Supplementary Data from Tilsotolimod Exploits the TLR9 Pathway to Promote Antigen Presentation and Type 1 IFN Signaling in Solid Tumors: A Multicenter International Phase I/II Trial (ILLUMINATE-101)
Hani M. Babiker, Erkut Borazanci, Vivek Subbiah, Sanjiv S. Agarwala et autres